These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 39017997)
1. Innovative approaches for vaccine trials as a key component of pandemic preparedness - a white paper. Bethe U; Pana ZD; Drosten C; Goossens H; König F; Marchant A; Molenberghs G; Posch M; Van Damme P; Cornely OA Infection; 2024 Jul; ():. PubMed ID: 39017997 [TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
3. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs. Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275 [TBL] [Abstract][Full Text] [Related]
4. VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe. Salmanton-García J; Wipfler P; Valle-Simón P; Merakou C; Kopsidas I; Bethe U; Steinbach A; Spivak O; Součková L; Mendonça MA; Koniordou M; Hellemans M; Frías-Iniesta J; Davis RJ; Barta I; Azzini AM; Askling HH; Argyropoulos CD; Álvarez-Barco E; Akova M; Bonten MMJ; Cohen-Kandli M; Cox RJ; Flisiak R; Husa P; Jancoriene L; Koscalova A; Launay O; Lundgren J; Mallon P; Marques L; Nauclér P; Ochando J; Pana ZD; Tacconelli E; Tóth K; Trelle S; van Damme P; Zaoutis TE; Zeitlinger M; Albus K; Stewart FA; Hofstraat SHI; Bruijning-Verhagen P; Cornely OA; Vaccine; 2023 Jun; 41(26):3915-3922. PubMed ID: 37210309 [TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
7. Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit. Argyropoulos CD; Leckler J; Salmanton-García J; Constantinou M; Alexandrou A; Themistocleous S; Noula E; Shiamakkides G; Nearchou A; Stewart FA; Albus K; Koniordou M; Kopsidas I; Spivak O; Hellemans M; Hendrickx G; Davis RJ; Azzini AM; Simon PV; Carcas-Sansuan AJ; Askling HH; Vene S; Prellezo JB; Álvarez-Barco E; Macken AJ; Di Marzo R; Luís C; Olesen OF; Frias Iniesta JA; Barta I; Tóth K; Akova M; Bonten MMJ; Cohen-Kandli M; Cox RJ; Součková L; Husa P; Jancoriene L; Launay O; Lundgren J; Mallon P; Armeftis C; Marques L; Naucler P; Ochando J; Tacconelli E; van Damme P; Zaoutis T; Hofstraat S; Bruijning-Verhagen P; Zeitlinger M; Cornely OA; Pana ZD JMIR Public Health Surveill; 2023 Apr; 9():e44491. PubMed ID: 36878478 [TBL] [Abstract][Full Text] [Related]
8. Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE Survey Study. Themistocleous S; Argyropoulos CD; Vogazianos P; Shiamakkides G; Noula E; Nearchou A; Yiallouris A; Filippou C; Stewart FA; Koniordou M; Kopsidas I; Askling HH; Vene S; Gagneux-Brunon A; Prellezo JB; Álvarez-Barco E; Salmanton-García J; Leckler J; Macken AJ; Davis RJ; Azzini AM; Armeftis C; Hellemans M; Di Marzo R; Luis C; Olesen OF; Valdenmaiier O; Jakobsen SF; Nauclér P; Launay O; Mallon P; Ochando J; van Damme P; Tacconelli E; Zaoutis T; Cornely OA; Pana ZD JMIR Public Health Surveill; 2024 Apr; 10():e47241. PubMed ID: 38573762 [TBL] [Abstract][Full Text] [Related]
9. Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO). McLeod C; Ramsay J; Flanagan KL; Plebanski M; Marshall H; Dymock M; Marsh J; Estcourt MJ; Wadia U; Williams PCM; Tjiam MC; Blyth C; Subbarao K; Nicholson S; Faust S; Thornton RB; Mckenzie A; Snelling TL; Richmond P Trials; 2023 Mar; 24(1):202. PubMed ID: 36934272 [TBL] [Abstract][Full Text] [Related]
10. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. Alexander BM; Trippa L; Gaffey S; Arrillaga-Romany IC; Lee EQ; Rinne ML; Ahluwalia MS; Colman H; Fell G; Galanis E; de Groot J; Drappatz J; Lassman AB; Meredith DM; Nabors LB; Santagata S; Schiff D; Welch MR; Ligon KL; Wen PY JCO Precis Oncol; 2019; 3():. PubMed ID: 32914038 [TBL] [Abstract][Full Text] [Related]
11. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
12. Conducting a bayesian multi-armed trial with response adaptive randomization for comparative effectiveness of medications for CSPN. Brown AR; Gajewski BJ; Mudaranthakam DP; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Mayo MS; Barohn RJ Contemp Clin Trials Commun; 2023 Dec; 36():101220. PubMed ID: 37965484 [TBL] [Abstract][Full Text] [Related]
13. A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization. Brown AR; Gajewski BJ; Aaronson LS; Mudaranthakam DP; Hunt SL; Berry SM; Quintana M; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Barohn RJ Trials; 2016 Aug; 17(1):428. PubMed ID: 27577191 [TBL] [Abstract][Full Text] [Related]
14. Innovative trial designs and analyses for vaccine clinical development. Liu M; Li Q; Lin J; Lin Y; Hoffman E Contemp Clin Trials; 2021 Jan; 100():106225. PubMed ID: 33227451 [TBL] [Abstract][Full Text] [Related]
15. PIPDeploy: Development and implementation of a gamified table top simulation exercise to strengthen national pandemic vaccine preparedness and readiness. Ghiga I; Richardson S; Álvarez AMR; Kato M; Naidoo D; Otsu S; Nguyen PT; Nguyen PN; Nguyen T Vaccine; 2021 Jan; 39(2):364-371. PubMed ID: 33293160 [TBL] [Abstract][Full Text] [Related]
16. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop. Coffey CS; Levin B; Clark C; Timmerman C; Wittes J; Gilbert P; Harris S Clin Trials; 2012 Dec; 9(6):671-80. PubMed ID: 23250942 [TBL] [Abstract][Full Text] [Related]
17. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial. Cerqueira FP; Jesus AMC; Cotrim MD Ther Innov Regul Sci; 2020 Jan; 54(1):246-258. PubMed ID: 32008232 [TBL] [Abstract][Full Text] [Related]
18. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial. Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). Oshansky CM; Zhou J; Gao Y; Schweinle JE; Biscardi K; DeBeauchamp J; Pavetto C; Wollish A; ; Webby RJ; Cioce V; Donis RO; Bright RA Vaccine; 2019 Jan; 37(3):435-443. PubMed ID: 30553570 [TBL] [Abstract][Full Text] [Related]
20. Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations. Manoharan L; Olliaro P; Horby PW; Watson CH Trials; 2021 May; 22(1):370. PubMed ID: 34051840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]